Targets › DHPS
3 programs from 3 companies in 3 trials: 2 Phase 4, 1 Phase 3; Infectious disease, Immunology; next expected readout Dec 2026.
Catalyzes the NAD-dependent oxidative cleavage of spermidine and the subsequent transfer of the butylamine moiety of spermidine to the epsilon-amino group of a critical lysine residue of the eIF-5A precursor protein to form the intermediate deoxyhypusine residue. This is the first step of the post-translational modification of that lysine into an unusual amino acid residue named hypusine. (UniProt, P49366)
Open in Phaseline: the race on DHPS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tongji Hospital | Trimethoprim Bacterial dihydrofolate reductase inhibitor | DHFR, DHPS | Phase 4 | Pneumonia, Pneumocystis | Dec 2026 |
| Indiana University | Trimethoprim-sulfamethoxazole (TMP-SMX) Dihydropteroate synthase and dihydrofolate reductase inhibitor; inhibits bacterial folate | DHPS, DHFR | Phase 4 | Methicillin Resistant Staphylococcus Aureus | Jun 2027 |
| Tampere University | Sulfadoxine Dihydropteroate synthetase inhibitor | DHPS, DHFR | Phase 3 | Malaria | Dec 2027 |
Malaria (1) Pneumonia, Pneumocystis (1) Methicillin Resistant Staphylococcus Aureus (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.